Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only modest efficacy. Combining the KRAS G12C inhibitor sotorasib with panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, may be an effective strategy. METHODS: G12C who had not received previous treatment with a KRAS G12C inhibitor to receive sotorasib at a dose of 960 mg once daily plus panitumumab (53 patients), sotorasib at a dose of 240 mg once daily plus panitumumab (53 patients), or the investigator's choice of trifluridine-tipiracil or regorafenib (standard care; 54 patients). The primary end point was progression-free survival as assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Key secondary end points were overall survival and objective response. RESULTS: After a median follow-up of 7.8 months (range, 0.1 to 13.9), the median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2 to 6.3) and 3.9 months (95% CI, 3.7 to 5.8) in the 960-mg sotorasib-panitumumab and 240-mg sotorasib-panitumumab groups, respectively, as compared with 2.2 months (95% CI, 1.9 to 3.9) in the standard-care group. The hazard ratio for disease progression or death in the 960-mg sotorasib-panitumumab group as compared with the standard-care group was 0.49 (95% CI, 0.30 to 0.80; P = 0.006), and the hazard ratio in the 240-mg sotorasib-panitumumab group was 0.58 (95% CI, 0.36 to 0.93; P = 0.03). Overall survival data are maturing. The objective response was 26.4% (95% CI, 15.3 to 40.3), 5.7% (95% CI, 1.2 to 15.7), and 0% (95% CI, 0.0 to 6.6) in the 960-mg sotorasib-panitumumab, 240-mg sotorasib-panitumumab, and standard-care groups, respectively. Treatment-related adverse events of grade 3 or higher occurred in 35.8%, 30.2%, and 43.1% of patients, respectively. Skin-related toxic effects and hypomagnesemia were the most common adverse events observed with sotorasib-panitumumab. CONCLUSIONS: In this phase 3 trial of a KRAS G12C inhibitor plus an EGFR inhibitor in patients with chemorefractory metastatic colorectal cancer, both doses of sotorasib in combination with panitumumab resulted in longer progression-free survival than standard treatment. Toxic effects were as expected for either agent alone and resulted in few discontinuations of treatment. (Funded by Amgen; CodeBreaK 300 ClinicalTrials.gov number, NCT05198934.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, KRAS G12C (glycine to cysteine) can be targeted using the covalent inhibitors, such as sotorasib, in combination with EGFR antagonists, such as panitumumab [75].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [75]
In the citing paper
“While KRAS and EGFR dual targeting holds promise in KRAS-mutant CRC, responses are often short-lived; most patients relapse within months due to acquired resistance.”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [6]
In the citing paper
“While dual KRAS and epidermal growth factor receptor (EGFR) inhibition shows promise in treating KRAS-mutant colorectal cancer (CRC), resistance remains a major challenge.”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [6]
In the citing paper
“the phase 3 CodeBreaK 300 trial comparing sotorasib at two doses (960 mg or 240 mg) plus panitumumab with investigator's choice of trifluridine/tipiracil or regorafenib in patients with chemotherapy-refractory KRAS G12C-mutated metastatic colorectal cancer was ongoing, and has shown improved progression-free survival with this combination strategy at both the doses tested. 19”
From Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial (2024) · cites this paper as [19]
In the citing paper
“Clinical studies of other KRAS G12C inhibitors, such as sotorasib and adagrasib, support this hypothesis, with higher response rates observed when used in combination with an EGFR inhibitor compared to when used as single-agent treatment in patients with CRC16–20.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [17]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Self-citationSotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationRandomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02088 · Cited by 569
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527
Cited by
Items 301–381 of 381
Deciphering KRAS inhibitor resistance
Torphy, R. J., & Pylayeva‐Gupta, Y. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01757-z
KRAS ‐ G12C : The neglected biomarker to detect patients with MUTYH ‐associated polyposis
Medeiros, A. B. D., dos Santos, G. O., da Rocha, J. C. C., Aguiar, S., Silva, V. S. E., Berardinelli, G. N., Antoniazzi, A. P., Reis, R. M., Carraro, D. M., & Torrezan, G. T. (2025) · International Journal of Cancer · doi:10.1002/ijc.70281
“26,27 In our cohort, 46.1% While KRAS somatic analysis is routinely performed in CRC using targeted NGS panels or comprehensive genomic profiles due to its prognostic and predictive relevance for KRAS-G12C targeted therapies, 28,29 the use of KRAS-G12C as a MAP biomarker remains neglected.”
InfluentialRatain, M. J., & Fojo, A. T. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01607
Kagawa, Y., Osaka, T., Imamura, T., & Kuwabara, H. (2025) · Cancers · doi:10.3390/cancers17243962 · Cited by 1
“Examples include sotorasib combined with panitumumab and adagrasib combined with cetuximab, which are emerging as promising approaches based on favorable clinical outcomes [40–42].”
Jang, M., Gysler, S. M., Latif, N., Ko, E. M., Giuntoli, R. L., Kim, S. H., Simpkins, F. A., & Nasioudis, D. (2025) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2025.102008
Adaptive plasticity in targeted therapy
Amodio, V., Patelli, G., & Bardelli, A. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.007
Grabiec, M., Raźniewska, D., Kałużewski, T., Krakowska, M., Radecka, B. S., & Potemski, P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15010332
“Additionally, the KRAS G12C mutation, present in 3% of colorectal cancer cases, allows for the use of dual-drug regimens such as sotorasib and panitumumab, based on the phase III CodeBreak 300 trial [7], or adagrasib and cetuximab, based on the phase I/II KRYSTAL-1 trial [8].”
Nindra, U., Hong, J. H., Hong, M., Lim, S. H.-S., Asghari, R., Farzin, M., Rutland, T., Chantrill, L., Brungs, D., Wong, M. K., et al. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101103 · Cited by 2
Lee, M. A. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0110
Hollander, E. M., Buma, A. I. G., Leentjens, J., Janssen, P. K. C., van den Heuvel, M. M., Burger, D. M., Piet, B., & ter Heine, R. (2026) · International Journal of Cancer · doi:10.1002/ijc.70326
“It also demonstrated promising efficacy in KRAS G12C mutated metastatic colorectal cancer 22,23 and advanced pancreatic cancer.”
Predictive biomarkers in clinical practice in colorectal cancer
Rodríguez-Castells, M., & Élez, E. (2026) · Revisiones en cáncer · doi:10.20960/revcancer.00131
Actionable subgroups (I): RAS (KRAS G12C) and BRAF V600E
Alonso-Orduña, V., Tobeña, M., & Marqués, E. P. (2026) · Revisiones en cáncer · doi:10.20960/revcancer.00134
Li, H., Chen, S., Kou, X., Tian, Y., Wu, C., Liu, H., & Qiu, J. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04198-2
“Thus, to ensure optimal outcomes, patients are screened for KRAS mutations prior to receiving panitumumab in the clinic [13].”
Third-line and beyond treatment in mCRC and sequencing
Maurel, J., & Piedra, M. R. (2026) · Revisiones en cáncer · doi:10.20960/revcancer.00130
Toxicities and support in targeted therapies and immunotherapy in colorectal cancer
Páez, D., & Munoz, M. N. (2026) · Revisiones en cáncer · doi:10.20960/revcancer.00133
Self-citationPretta, A., Ziranu, P., Bergamo, F., Bottelli, A., Marmorino, F., Masiello, M., Mariani, S., Cerma, K., Ghelardi, F., Ciracì, P., et al. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.02.002
Self-citationMarko, M., Kukic, B. P., Kolarov-Bjelobrk, I., Nemanja, P., Aleksandar, D., Novak, S., & Urosevic, T. (2025) · Journal of Medical and Radiation Oncology · doi:10.53011/jmro.2025.02.03
Integrative approaches to colorectal cancer
Lee, R. W., Bahri, N., Kim, E., Blarigan, E. L. V., Wood, K. C., & Atreya, C. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30194-0.00027-8
Frisch, A., Martin, E., Cannon, T. L., Wadlow, R. C., Raghavan, S., Sen, T., & Karim, N. A. (2026) · Current Oncology · doi:10.3390/curroncol33030148
“Similarly, in CodeBreaK 101, sotorasib combined with panitumumab demonstrated an ORR of approximately 30% in 40 patients with KRAS G12C–mutant CRC, with grade ≥ 3 TRAEs occurring in approximately 27% of patients [36].”
Advancements and innovations in the molecular mechanisms and treatment of colorectal cancer
Wang, X., & Yang, J. (2026) · Discover Oncology · doi:10.1007/s12672-026-04796-6 · Cited by 1
“A phase III randomized controlled trial (CodeBreaK 300) is currently underway, with promising preliminary results at a median follow-up of 7.8 months [74].”
InfluentialConstitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors
Kanemura, H., Takehara, T., Maenishi, O., Tomida, S., Iwawaki, N., Kunimasa, K., Nakayama, T., Watanabe, S., Suzuki, S., Sakai, K., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0489
“Furthermore, dual blockade of EGFR and KRAS G12C signaling was previously found to be more effective than treat-ment with an EGFR inhibitor or KRAS G12C inhibitor alone in some cancer cells harboring the KRAS G12C mutation (15, 38, 39).”
Edwards, G. O., Causi, F. S. L., Castagnola, G., Singh, S., & Amendola, P. G. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1777400
Huemer, F., Piringer, G., Eisterer, W., Heibl, S., Rumpold, H. F., Wöll, E., Schreil, G., Sliwa, T., Winder, T. L., Prager, G. W., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2644463 · Cited by 1
“The therapeutic armamentarium ≥third-line (3 L) has continuously evolved in recent years and has improved clinical outcome among mCRC “all-comers” as well as biomarker-driven mCRC sub-cohorts [7–13].”
From undruggable to actionable: advances in KRAS targeting in colorectal cancer
Chan, M., Shelke, M., Townsend, A. R., Roy, A. C., Broadbridge, V. T., Karapetis, C. S., & Price, T. J. (2026) · Academia oncology. · doi:10.20935/acadonco8216
Innovative targeted therapies for mosaic RAS-related vascular malformations
Morin, G. (2024) · theses.fr (ABES) · doi:10.70675/88882e5fz1bf9z4dbezae13zba4200ee9598
Thielen, N., Wei, N., Nagai, E., Houston, M. A., Augenlicht, L. H., Shin, A. E., Gabre, J. T., Rustgi, A. K., Ha, G., LaFave, L. M., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01384-3 · Cited by 1
“This dual blockade signi fi cantly improved outcomes, with the 960 mg Sotorasib plus Panitu-mumab arm achieving a median progression-free survival (PFS) of 5.6 monthsandanoverallresponserate(ORR)of26%,superiortostandard-of-carechemotherapy(3.9monthsand0%,respectively) 21,22 .”
InfluentialMarni, N. B., Singuluri, J. N. S., Saragam, J. R. L., et al. (2026) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3503
Burge, M., Tie, J., Krishnan, T., Roy, A., Chantrill, L., Tebbutt, N. C., Karapetis, C. S., & Price, T. J. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.04.001 · Cited by 1
Context defines precision: rethinking KRAS inhibition in oncology
Marchiò, S. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01422-0 · Cited by 1
“For clarity, resistance to KRAS inhibition can be grouped into four mechanistic classes 37 – 42 .”
Abraham, A., & Jayakrishnan, T. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01271 · Cited by 1
Salvatore, L., Fakih, M., Kuboki, Y., Hong, D. S., Modest, D. P., Taïeb, J., Price, T. J., Cremolini, C., Majer, I. M., Rehn, M., et al. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.04.003 · Cited by 1
Self-citationGrancher, A., Landi, M., Ballhausen, A., Tocino, R. V., Alig, A. H. S., Taravella, A., Malicot, K. L., Soularue, É., Gallois, C., Guarssifi, M., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.04.009
Self-citationAcosta, E. C. (2026) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2026.04.006
Targeting KRAS G12C in Rare Mesonephric Carcinoma of the Cervix: A Promising Response to Sotorasib
Li, B. C. W., Li, J. J. X., Tse, K. Y., Lu, H., & Chan, K. K. L. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01077
Samaille, T., Raeisi, M., Cohen, R., Shi, Q., Yoshino, T., Zalcberg, J. R., Adams, R., Cremolini, C., Grothey, A. F., Mayer, R. J., et al. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.05.007
Self-citationLi, Y., Zhou, M., Pan, J., Su, H., Song, M., Guan, Z., Zhao, D., Zhao, X., Zhao, Y., Chen, P., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102821
“At present, clinical trials evaluating AMG510 in combination with EGFR antibodies or immune checkpoint inhibitors are ongoing, with multiple studies aiming to increase AMG510 efficacy by blocking bypass activation and relieving immunosuppression [22 – 24].”
Pisapia, P., Iaccarino, A., Luca, C. D., Pepe, F., Russo, G., Nacchio, M., Giovanni, D. D., Cozzolino, D., Conticelli, F., Palumbo, L., et al. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04374-w
Karahan, L., Arslan, S., & Dızdar, Ö. (2026) · Cureus · doi:10.7759/cureus.110414
“…modest activity in KRAS G12C-mutated CRC [5], but combining KRAS-G12C inhibition with EGFR blockade enhances efficacy, has yielded higher response rates in early studies and is now being evaluated in phase III trials [6,7] and recently (in early 2025) approved by the FDA for KRAS G12C-mutated CRC.”
Advances in multimodal therapy for peritoneal metastasis from colorectal cancer
Cao, Y.-Q., Wu, Q.-B., Wang, Z., & Meng, W. (2026) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v34.i5.404
Aguiari, G., Bianchi, N., & Franzese, O. (2026) · Cells · doi:10.3390/cells15121074
Choi, P. H., Meredith, J., Sharma, M., Chen, X., Qiu, J., Markov, V., de Stanchina, E., Singh, M., & Rosen, N. X. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117559 · Cited by 2
Hsu, F.-C., Pu, T., Lin, J.-C., & Chen, C. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102872
“…for treatment prediction, detecting low-level KRAS G12 mutations offers distinct advantages for screening and surveillance pathways because it enables the identification of high-risk precancerous lesions (present in > 50% of advanced adenomas) and facilitates personalized surveillance [16,17].”
作山洋貴, Okuyama, H., Tahara, Y., Tsukamoto, S., Kita, I., Nomura, K., Murakami, A., Okita, Y., Satake, H., Kato, T., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03101-3
The role of magnesium in colorectal cancer: mini-review
Vázquez-Prieto, M. D. L. Á., & Sumoza‐Toledo, A. (2026) · ONCOLOGIE · doi:10.1515/oncologie-2026-0058
“Furthermore, recent advances in targeted therapies, including KRAS G12C inhibitors such as sotorasib and adagrasib, highlight the importance of this pathway in clinical oncology [78 – 80].”
Miolo, G., Marus, W., Canil, G., Inversi, A., Puglisi, F., & Corona, G. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6c00178 · Cited by 1
Therapeutic inhibition of RAS in non-small cell lung cancer
Nichols, K. B., & Herzberg, B. O. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1817943
“By contrast, in a study in colorectal cancer (CRC) of sotorasib combined with the EGFR monoclonal antibody panitumumab, differences between the dose groups was much more stark: at 960mg the response rate was 26.4% and PFS 5.6 months, versus 5.7% and 3.9 months in the 240mg group (68).”
InfluentialTargeting KRAS for cancer therapy
Jia, J., Liu, R., Adamide, T. A., Fernandez, I. E., & Stathopoulos, G. T. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70546 · Cited by 4
Jiang, L., Luo, Y., Liang, H., Feng, X., Huang, Y., Li, Y., Wang, Z., Xu, T., Zou, H., Li, Z., et al. (2026) · Human Cell · doi:10.1007/s13577-026-01405-0
“…of allele-specific covalent inhibitors, such as sotorasib and adagrasib that trap KRAS G12C in its inactive GDP-bound state, has revolutionized the therapeutic landscape for KRAS G12C mutant cancers, demonstrating clinically meaningful efficacy and leading to regulatory approvals [1, 7, 8].”
Yifeng, L., Nanjo, S., Murase, Y., Arai, S., Watanabe, S., Tsuda, T., Suzuki, J., Taniguchi, H., Shibata, K., Sato, S., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03877-8
Sagawa, T., Nagashima, H., & Fujikawa, K. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01524-9
Chang, P., Hsieh, M., Teng, H., Liang, Y.-H., Chen, H.-H., Hsu, H., Jiang, J., Chiang, F., Lin, J. Y., Lin, B., et al. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261457553
Yan, Y., Zheng, L., Wang, H., Sun, L., & Xu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1848431
“Eventually, 4 studies (16, 18, 25, 26) with 3 RCTs were included in this review.”
InfluentialHernandez, A. E., Borowsky, P. A., Cash, C. J., et al. (2026) · Cancers · doi:10.3390/cancers18142301
“Median intensive care unit LOS (3 [2–5] vs. 3 [2–6] days; p = 0.803) and overall hospital LOS (10 [7–15] vs. 9 [7–12] days; p = 0.256) did not differ between mut KRAS and wildtype KRAS groups (Table 2).”
InfluentialYang, X., Tao, X., Qi, W., Luo, R., Lan, T., Xie, K., Cai, Y., Gao, F., Lv, Y., Liu, C., et al. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101718
Wang, Z. Q., Hong, D., Zhang, L. P., Qin, Y., Guo, Z., Huo, Y., Shi, Y., Lu, Y., Li, B., & Su, S. (2026) · The Oncologist · doi:10.1093/oncolo/oyag263
Xing, Y.-R., Wang, S.-F., Dai, J.-J., Xu, X.-G., & Mao, W.-J. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.119680
Salih, R., Sirajudeen, F., & Rahmani, M. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.08.030 · Cited by 1
Benidovskaya, E., Huyghe, N. D., Giolito, M. V., Coulie, P. G., & den Eynde, M. V. (2026) · Cancers · doi:10.3390/cancers18162651
“Notably, the KRAS G12C mutation, present in approximately 3–4% of mCRC, has spurred the development of specific covalent inhibitors, with sotorasib and adagrasib demonstrating clinical activity in pretreated patients when combined with anti-EGFR treatment [14,15].”
KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions
Sagawa, T., Nagashima, H., & Fujikawa, K. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01547-2
Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers
Kos, M., Bojarski, K., Czosnek, M., Śnieżyński, J., Wilczyński, B., Mertowska, P., Grywalska, E., & Mertowski, S. (2026) · Cancers · doi:10.3390/cancers18162675 · Cited by 1
Matsubara, Y., & Kawazoe, A. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2717151
Masuishi, T., Strickler, J. H., Kuboki, Y., Fakih, M., Greil, R., Galot, R., Price, T. J., Élez, E., Siena, S., Hippenmeyer, J., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108338 · Cited by 10
“2,7 The plasma concentration levels of irinotecan and its active metabolite SN-38 between days 1 and 15 were within the therapeutic range reported previously.”
InfluentialSelf-citationSong, Z., Zhu, L., Liu, Y., Lin, R., Li, X., Luo, Y., Yuan, Y., Shi, H., Zhang, Y., Zhang, B., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00175-0 · Cited by 1
Kwiatkowska, L., & Szczuko, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177559
“The clinical activity of sotorasib plus pan-itumumab in KRAS G12C-mutated mCRC provides strong evidence that panitumumab may retain therapeutic relevance even in selected RAS -mutant tumors when the oncogenic driver is directly inhibited [60,61].”
InfluentialKRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target
Iftikhar, S., Xiao, A. H., Jin, Z., & Aly, E. H. (2026) · Current Oncology · doi:10.3390/curroncol33090514
“To date, sotorasib plus panitumumab as well as adagrasib plus cetuximab are approved options for adults with KRAS G12C-mutated metastatic CRC after prior fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy [71].”
Chen, Y.-L., Chen, W.-C., Yeh, T., Ho, H.-H., Chen, T.-C., & Wang, W. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101036
RAS-targeted therapies for pancreatic cancer
Chan, L. L., Kwong, T. T., Yau, J., & Chan, S. L. (2026) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2026.100414
“65,66 Unfortunately, preclinical studies indicate response with this approach in only a minor subset of PDAC models with epithelial differentiation.”
Thanabalachandran, L., Ali, D., Newman-Simmons, A., Norman, C., Jafari, D., Grahovac, T., Pollett, A. F., Huang, W., Chen, L., Kassam, S. N., et al. (2026) · Current Oncology · doi:10.3390/curroncol33090540
Mutant KRAS‐m 6 A Epitranscriptome Axis Promotes Colorectal Cancer and is a Therapeutic Target
Chen, D., Huang, P., Tao, R., Ji, F., Wei, Q., Ko, L. H., Zhou, L., Chen, H., Cheung, A. H. K., Kang, W., et al. (2026) · Advanced Science · doi:10.1002/advs.77627
Chatterjee, S., Arya, S., Sharma, N., Grover, M., Yadav, D., & Parveen, H. (2026) · Medical Oncology · doi:10.1007/s12032-026-03392-6
Organerhalt beim Rektumkarzinom
Fokas, E., Dapper, H., Diefenhardt, M., Damanakis, A. I., Schiffmann, L., Fuchs, H., Bruns, C., Rödel, C. M., & Dieplinger, G. (2026) · Die Onkologie · doi:10.1007/s00761-026-02015-z
Beyond the breakthrough for RAS-driven cancers
King, R. E. C., Tsang, E. S., & Knox, J. J. (2026) · Nature Medicine · doi:10.1038/s41591-026-04610-4
Tsai, Y.-T., Hsu, W., & Chuang, C.-H. (2026) · Journal of Cancer Research and Practice · doi:10.4103/ejcrp.ejcrp-d-25-00040
Aceituno, L., Valenzi, E., Segatto, O., Saborowski, A. L., & Vogel, A. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.102619
External Validation of the ARCAD Nomogram in a Real-World Cohort with Stage 4 Colorectal Cancer
Yu, J. B., Li, J., Schell, M. J., Ginestet, P. G., Zalcberg, J. R., Simes, R. J., Marschner, I., Kim, R. D., & Sjoquist, K. M. (2026) · Cancers · doi:10.3390/cancers18183031
Next-generation tumor-agnostic targets on the horizon
Coleman, N., Liu, J., Beal, J. R., & Subbiah, V. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.08.009
Gonçalves, M. P. C., Trocoli-Couto, P. H. F. S., Marchiodi, A. H., de Carvalho, L. T. B., Yamashita, Y. P. H., Lima, H. A., & Resende, V. (2026) · Cancers · doi:10.3390/cancers18193070
Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer
Kreidi, J., Hoyek, C., Eslinger, C. R., & Bekaii-Saab, T. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2738708
Wan, K., Tang, K., Wang, L., Tian, Q., Zheng, M., Qian, C., & 刘丽梅 (2026) · MedComm · doi:10.1002/mco2.71028
Fattakhova, A. S., Валентинович, Ч. С., & Shiryaev, N. P. (2026) · Medical alphabet · doi:10.33667/2078-5631-2026-15-46-53
KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine
Cai, J., Wu, Y., Jia, X., Yang, L., Yang, W., Lu, W., Huang, Z., Pan, Y., Fei, Z., Ru, J., et al. (2026) · MedComm · doi:10.1002/mco2.71050 · Cited by 1
“While single-agent KRAS G12C inhibitors are generally manageable, combination strategies with immunotherapy, chemotherapy, or other targeted agents may increase treatment-related toxicity and complicate dose intensity, scheduling, and treatment adherence [ 77, 78 ].”
Metadata
- Authors
- Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., Meriggi, F., Cunningham, D., Yeh, K.-H., Chan, E., Chao, J., Saportas, Y., Tran, Q., Cremolini, C., & Pietrantonio, F.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte (M.G.F.), and Amgen, Thousand Oaks (E.C., J.C., Y.S., Q.T.) — both in California; Oncologia Medica, Università Cattolica del Sacro Cuore, and Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome (L.S.), the Oncology Department, Fondazione Poliambulanza Istituto Ospedaliero, Brescia (F.M.), the Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa (C.C.), and the Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan (F.P.) — all in Italy; the Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka (T.E.), and the Experimental Therapeutics and GI Oncology Department, National Cancer Center Hospital East, Kashiwa (Y.K.) — both in Japan; the Medicine Department of Hemato...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-07
- Volume
- 389
- Issue
- 23
- Pages
- 2125-2139
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387859726
- Semantic Scholar
- 775955729cc149c0cdcaed25ee8100657413b921
- Cited by
- 398
- References
- 37
- Citations by year
- 2026: 127 · 2025: 143 · 2024: 121 · 2023: 7
- FWCI
- 48.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- Amgen (NA)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- sotorasib, panitumumab, KRAS G12C mutation, metastatic colorectal cancer, EGFR inhibition, KRAS G12C inhibitors, combination therapy, progression-free survival, overall survival, objective response, trifluridine/tipiracil, regorafenib, dose comparison, refractory cancer, targeted therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Panitumumab, Immune Checkpoint Inhibitors, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Mutation, Phenylurea Compounds, Piperazines, Pyridines, Pyrimidines, Pyrrolidines, Thymine, Trifluridine, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.